OncLive Staff
Articles
FDA Granted Enzalutamide Priority Review to Treat Metastatic Hormone-Sensitive Prostate Cancer
August 22, 2019
Article
The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), according to Astellas Pharma Inc. and Pfizer Inc., the codevelopers of the androgen receptor inhibitor.
FDA Approves Venetoclax Plus Obinutuzumab for CLL Treatment
May 15, 2019
Article
The FDA has approved the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) for the frontline treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA Approves Atezolizumab Combo for Frontline TNBC
March 08, 2019
Article
The Food and Drug Administration has granted an accelerated approval to the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC)
FDA Grants Priority Review to Selinexor for Penta-Refractory Multiple Myeloma
October 08, 2018
Article
The FDA has granted a priority review to the XPO1 inhibitor selinexor for the treatment of patients with penta-refractory multiple myeloma.